Corona: What measures have Governments taken in the Life Sciences Sector?
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
Governments have been implementing different emergency measures in the fight against the current pandemic. The Baker McKenzie Healthcare and Life Sciences Industry Group has now published an interesting overview of the different measures that various governments across the EMEA region (Europe, Middle East, Asia) have adopted in the area of healthcare and life sciences in response to the COVID-19 outbreak.
In this document, Baker McKenzie lawyers across EMEA share their high-level views on the following areas:
- Requisition powers
- Price and reimbursement
- Public procurement
- Legal deadlines
- Relaxation of regulatory rules
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years